212 related articles for article (PubMed ID: 37539777)
1. TAZ upregulates MIR-224 to inhibit oxidative stress response in multiple myeloma.
Abegunde SO; Grieve S; Reiman T
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1879. PubMed ID: 37539777
[TBL] [Abstract][Full Text] [Related]
2. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.
Grieve S; Wajnberg G; Lees M; Chacko S; Weir J; Crapoulet N; Reiman T
Blood Adv; 2019 Nov; 3(22):3613-3625. PubMed ID: 31743393
[TBL] [Abstract][Full Text] [Related]
3. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation.
Zhang Y; Xue C; Zhu X; Zhu X; Xian H; Huang Z
Cell Signal; 2016 Aug; 28(8):850-60. PubMed ID: 27094723
[TBL] [Abstract][Full Text] [Related]
4. MST1 downregulates TAZ tumor suppressor protein in multiple myeloma and is a potential therapeutic target.
Abegunde SO; Grieve S; Alfarra H; Reiman T
Exp Hematol; 2023 Jul; 123():34-45. PubMed ID: 37137439
[TBL] [Abstract][Full Text] [Related]
5. TAZ deficiency impairs the autophagy-lysosomal pathway through NRF2 dysregulation and lysosomal dysfunction.
Kim HK; Jeong H; Jeong MG; Won HY; Lee G; Bae SH; Nam M; Lee SH; Hwang GS; Hwang ES
Int J Biol Sci; 2024; 20(7):2592-2606. PubMed ID: 38725855
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas.
Escoll M; Lastra D; Pajares M; Robledinos-Antón N; Rojo AI; Fernández-Ginés R; Mendiola M; Martínez-Marín V; Esteban I; López-Larrubia P; Gargini R; Cuadrado A
Redox Biol; 2020 Feb; 30():101425. PubMed ID: 31918259
[TBL] [Abstract][Full Text] [Related]
7. The TAZ-miR-224-SMAD4 axis promotes tumorigenesis in osteosarcoma.
Ma J; Huang K; Ma Y; Zhou M; Fan S
Cell Death Dis; 2017 Jan; 8(1):e2539. PubMed ID: 28055015
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
Pichiorri F; Suh SS; Ladetto M; Kuehl M; Palumbo T; Drandi D; Taccioli C; Zanesi N; Alder H; Hagan JP; Munker R; Volinia S; Boccadoro M; Garzon R; Palumbo A; Aqeilan RI; Croce CM
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12885-90. PubMed ID: 18728182
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
11. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
[TBL] [Abstract][Full Text] [Related]
12. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
13. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.
Zhao JJ; Lin J; Zhu D; Wang X; Brooks D; Chen M; Chu ZB; Takada K; Ciccarelli B; Admin S; Tao J; Tai YT; Treon S; Pinkus G; Kuo WP; Hideshima T; Bouxsein M; Munshi N; Anderson K; Carrasco R
Cancer Res; 2014 Mar; 74(6):1801-13. PubMed ID: 24599134
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
[TBL] [Abstract][Full Text] [Related]
15. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
[No Abstract] [Full Text] [Related]
16. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.
Sun Y; Jiang T; Jia Y; Zou J; Wang X; Gu W
Cell Cycle; 2019 Oct; 18(19):2509-2523. PubMed ID: 31397203
[TBL] [Abstract][Full Text] [Related]
17. MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ.
Yuan J; Xiao G; Peng G; Liu D; Wang Z; Liao Y; Liu Q; Wu M; Yuan X
Biochem Biophys Res Commun; 2015 Feb; 457(2):171-6. PubMed ID: 25542152
[TBL] [Abstract][Full Text] [Related]
18. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
19. Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells.
Feng M; Luo X; Gu C; Fei J
J Drug Target; 2015 Jan; 23(1):59-66. PubMed ID: 25185784
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine.
Luo X; Gu J; Zhu R; Feng M; Zhu X; Li Y; Fei J
BMC Syst Biol; 2014 Jul; 8():82. PubMed ID: 25000828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
